Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsLymphocyte differentiation antigen CD38

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesCelularity Inc Sorrento Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesSorrento Therapeutics Inc Celularity Inc

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A